RxDoctor Payments Data

Henry Heaton, MD

MOHS-Micrographic Surgery · New York, NYNPI 1053798900

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 31.4% of the total. Reporting peaked in 2021 at $288 and has fallen 84.2% since, to $45 in 2024. That places this record below the midpoint for mohs-micrographic surgery clinicians in NY, where the typical reported total is $1,291.

$510in general payments, 2019–2025

Across 21 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$160
  • Lilly USA, LLC$92
  • AbbVie$82
  • Amgen$59
  • VYNE Pharmaceuticals Inc.$39
  • Almirall LLC$31
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510 in reported general payments places this provider in the 30th percentile of 75 mohs-micrographic surgery providers in New York.

See all mohs-micrographic surgery providers in New York

Medicare billing

Part B allowed, 2024
$759,243
Medicare patients
859
Services billed
5,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole201$3,985
Clobetasol Propionate96$3,661
Mupirocin337$2,588
Fluorouracil25$2,056
Calcipotriene13$1,934
Triamcinolone Acetonide99$1,466
Halobetasol Propionate22$1,239
Metronidazole23$988
Doxycycline Hyclate96$900
Clindamycin Phosphate22$866
ValacyclovirValacyclovir Hcl51$560
Gentamicin Sulfate14$501
Cephalexin89$381
Hydrocortisone27$222

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →